Infliximab to prevent side effects during myeloma treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with multiple myeloma that has come back or stopped responding to treatment.
- You must have tried at least 4 prior treatments, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
- You need to have measurable disease, like certain protein levels in blood or urine.
- You must have adequate blood counts, kidney, liver, and heart function.
- You cannot have active infections, including tuberculosis, or a history of severe allergic reactions to similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving an immunotherapy drug (talquetamab) before CAR T-cell therapy (cilta-cel) to see if it helps people with multiple myeloma that has come back or stopped responding to other treatments.
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
This trial tests two new medicines, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this combination can shrink the cancer and help you feel better.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
Hear when a new Cytokine Release Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.